BioLineRx Pops 34% On ‘Positive’ Results From Cancer Stem Cell Trial, , on November 1, 2020 at 1:28 pm

By ILP
On 11/01/2020
In Financial News
Tags:

Shares of BioLineRx Ltd. skyrocketed 34% on Oct. 30 after the clinical-stage biopharma company disclosed “positive” results from its ongoing Phase 3 trial of motixafortide used in the treatment for stem cell mobilization (SCM) in multiple myeloma patients.BioLineRx (BLRX) said that an independent Data Monitoring Committee (DMC) analyzing the study’s primary endpoint recommended that based on the statistically significant evidence favoring treatment with motixafortide, the company may already cease patient enrollment. Following the recommendation, BioLineRx said that the study enrollment is now completed with 122 patients. The study originally planned to recruit 177 patients.Primarily focused on oncology, BioLineRX in-licenses cutting-edge compounds, develops them through clinical stages and then partners with pharmaceutical companies for further clinical development.Full results of the motixafortide study are expected to be announced in the first half of 2021, including secondary and exploratory efficacy endpoints, as well as extended safety data, after the last patient enrolled reaches 100 days of follow-up post-transplantation.”The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company’s most efficient path to registration for motixafortide,” stated BioLineRx CEO Philip Serlin. “Stem cell mobilization represents a significant unmet medical need in multiple myeloma, as between 50% and 70% of patients are poor mobilizers. We eagerly await the final results of the study, which we hope will support our goal of changing the treatment paradigm in autologous stem-cell mobilization, thus positioning motixafortide in combination with G-CSF as the new standard of care in this indication.”  The motixafortide trial was initiated in December 2017. The study is a randomized, placebo-controlled trial, evaluating the safety, tolerability and efficacy of motixafortide and G-CSF (granulocyte-colony stimulating factor), compared to placebo and G-CSF, for the mobilization of HSCs (hematopoietic stem cells) for autologous transplantation in multiple myeloma patients.The primary objective of the study is to demonstrate that only one dose of motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize cells in up to two apheresis sessions. Secondary objectives include time to engraftment of neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters.BLRX shares are down 11% from the start of the year and the stock scores a bullish Strong Buy analyst consensus backed up by 3 recent unanimous Buy ratings. Looking ahead, the $11.33 average price target, indicates investors could be reaping a stellar 472% gain in the coming 12 months.Among the three analysts taking a bullish approach, Maxim Group’s Jason McCarthy on Oct. 30 reiterated his Buy rating on the stock with a $5 price target.“It is important to consider that motixafortide has wide potential applicability beyond just multiple myeloma, which could make it especially attractive for a partner with the resources to fund expansion,” McCarthy wrote in a note to investors. “Expansion of motixafortide to other hematologic indications for stem cell mobilization (such as non-hodgkins lymphoma or sickle cell) could greatly increase market size with just an incremental increase in associated operating expenses (the stem cell transplantation market is concentrated, and many of the transplant centers handle multiple indications), unlocking additional value for investors.” (See BioLineRx stock analysis on TipRanks)Related News: AstraZeneca Sells Rights To Hypertension Drugs For $400M Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3% Opko Health Tanks 10% Despite Solid Q3 Covid Testing Revenue More recent articles from Smarter Analyst: * Carlyle To Buy Flender From Siemens In $2.4B Deal; Analyst Sees 65% Upside * Nestle Snaps Up Freshly for $950M * ON Semiconductor Quarterly Profit Beats The Street; Analyst Says Buy * L3Harris Technologies Scores $97.51M Air Force Contract,

BioLineRx Pops 34% On ‘Positive’ Results From Cancer Stem Cell TrialShares of BioLineRx Ltd. skyrocketed 34% on Oct. 30 after the clinical-stage biopharma company disclosed “positive” results from its ongoing Phase 3 trial of motixafortide used in the treatment for stem cell mobilization (SCM) in multiple myeloma patients.BioLineRx (BLRX) said that an independent Data Monitoring Committee (DMC) analyzing the study’s primary endpoint recommended that based on the statistically significant evidence favoring treatment with motixafortide, the company may already cease patient enrollment. Following the recommendation, BioLineRx said that the study enrollment is now completed with 122 patients. The study originally planned to recruit 177 patients.Primarily focused on oncology, BioLineRX in-licenses cutting-edge compounds, develops them through clinical stages and then partners with pharmaceutical companies for further clinical development.Full results of the motixafortide study are expected to be announced in the first half of 2021, including secondary and exploratory efficacy endpoints, as well as extended safety data, after the last patient enrolled reaches 100 days of follow-up post-transplantation.”The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company’s most efficient path to registration for motixafortide,” stated BioLineRx CEO Philip Serlin. “Stem cell mobilization represents a significant unmet medical need in multiple myeloma, as between 50% and 70% of patients are poor mobilizers. We eagerly await the final results of the study, which we hope will support our goal of changing the treatment paradigm in autologous stem-cell mobilization, thus positioning motixafortide in combination with G-CSF as the new standard of care in this indication.”  The motixafortide trial was initiated in December 2017. The study is a randomized, placebo-controlled trial, evaluating the safety, tolerability and efficacy of motixafortide and G-CSF (granulocyte-colony stimulating factor), compared to placebo and G-CSF, for the mobilization of HSCs (hematopoietic stem cells) for autologous transplantation in multiple myeloma patients.The primary objective of the study is to demonstrate that only one dose of motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize cells in up to two apheresis sessions. Secondary objectives include time to engraftment of neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters.BLRX shares are down 11% from the start of the year and the stock scores a bullish Strong Buy analyst consensus backed up by 3 recent unanimous Buy ratings. Looking ahead, the $11.33 average price target, indicates investors could be reaping a stellar 472% gain in the coming 12 months.Among the three analysts taking a bullish approach, Maxim Group’s Jason McCarthy on Oct. 30 reiterated his Buy rating on the stock with a $5 price target.“It is important to consider that motixafortide has wide potential applicability beyond just multiple myeloma, which could make it especially attractive for a partner with the resources to fund expansion,” McCarthy wrote in a note to investors. “Expansion of motixafortide to other hematologic indications for stem cell mobilization (such as non-hodgkins lymphoma or sickle cell) could greatly increase market size with just an incremental increase in associated operating expenses (the stem cell transplantation market is concentrated, and many of the transplant centers handle multiple indications), unlocking additional value for investors.” (See BioLineRx stock analysis on TipRanks)Related News: AstraZeneca Sells Rights To Hypertension Drugs For $400M Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3% Opko Health Tanks 10% Despite Solid Q3 Covid Testing Revenue More recent articles from Smarter Analyst: * Carlyle To Buy Flender From Siemens In $2.4B Deal; Analyst Sees 65% Upside * Nestle Snaps Up Freshly for $950M * ON Semiconductor Quarterly Profit Beats The Street; Analyst Says Buy * L3Harris Technologies Scores $97.51M Air Force Contract

,

Contact Us

Please use our Instant Quote form to see if you're pre-qualified for a non-recourse stock loan, or if you have any questions or feedback, please email, call or chat with us.

deals@internationalliquiditypartners.com

+44 20 3994 1588

Headquarters: Hunkins Waterfront Plaza, Charlestown, Nevis

Open 24 hours a day / 7 days a week / 365 days a year

 

 

 

Frequently Asked Questions

What Is Securities-Based Lending?
Securities-based lending, or a stock loan, is the practice of using market investments such as stocks, ETF’s, warrants, bonds, or real estate investment trusts as collateral for a loan.
How much money can I get for my securities?
Borrow up to 80% of the value of your pledged investments giving you the capital you need to expand your business, purchase real estate, or tackle a costly project.
What happens if my securities lose value?
With a non-recourse stock loan, you can walk away from your securities at any time and keep the loan money with no negative credit consequences even if the investments lose value.
Is my information safe with ILP?
We pride ourselves on outstanding service and make client confidentiality our top priority. You can always be absolutely certain your information is safe with us.
How long does it take for the disbursement of funds?
Most of the transactions we process take less than 7 days from application to the disbursement of funds giving you cash quickly when you need it most.
What credit score do I need to qualify?
There are no credit checks or personal guarantees necessary with our services. Your pledged securities are the only collateral required for the loan you receive.

Instant Quote

Please fill out your information to see if you are pre-qualified.

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

International Liquidity Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

International Liquidity Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with International Liquidity Partners, LLC’s internal lending policies. International Liquidity Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Nevis Office

Main Street
Hunkins Waterfront Plaza
Charlestown, Nevis

New York Office

Coming Soon!

Follow Us

Market Coverage